176 related articles for article (PubMed ID: 28182271)
1. Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer.
Dagogo-Jack I; Shaw AT; Riely GJ
Clin Pharmacol Ther; 2017 May; 101(5):625-633. PubMed ID: 28182271
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of the anaplastic lymphoma kinase.
Mologni L
Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
[TBL] [Abstract][Full Text] [Related]
3. The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer.
D'Arcangelo M; Wynes MW; Hirsch FR
Curr Opin Oncol; 2013 Mar; 25(2):121-9. PubMed ID: 23385859
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.
Katayama R; Lovly CM; Shaw AT
Clin Cancer Res; 2015 May; 21(10):2227-35. PubMed ID: 25979929
[TBL] [Abstract][Full Text] [Related]
5. Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma.
Cheng M; Ott GR
Anticancer Agents Med Chem; 2010 Mar; 10(3):236-49. PubMed ID: 20406193
[TBL] [Abstract][Full Text] [Related]
6. Targeting anaplastic lymphoma kinase in lung cancer.
Shaw AT; Solomon B
Clin Cancer Res; 2011 Apr; 17(8):2081-6. PubMed ID: 21288922
[TBL] [Abstract][Full Text] [Related]
7. Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas.
Boi M; Zucca E; Inghirami G; Bertoni F
Br J Haematol; 2015 Mar; 168(6):771-83. PubMed ID: 25559471
[TBL] [Abstract][Full Text] [Related]
8. ALK-immunoreactive neoplasms.
Minoo P; Wang HY
Int J Clin Exp Pathol; 2012; 5(5):397-410. PubMed ID: 22808292
[TBL] [Abstract][Full Text] [Related]
9. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
Toyokawa G; Seto T
Clin Lung Cancer; 2014 Sep; 15(5):313-9. PubMed ID: 24984564
[TBL] [Abstract][Full Text] [Related]
10. Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.
Landi L; Cappuzzo F
Expert Rev Clin Pharmacol; 2016; 9(2):203-14. PubMed ID: 26582431
[TBL] [Abstract][Full Text] [Related]
11. Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors.
Amin AD; Rajan SS; Liang WS; Pongtornpipat P; Groysman MJ; Tapia EO; Peters TL; Cuyugan L; Adkins J; Rimsza LM; Lussier YA; Puvvada SD; Schatz JH
Cancer Res; 2015 Jul; 75(14):2916-27. PubMed ID: 26018086
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer.
Katayama R
Pharmacol Ther; 2017 Sep; 177():1-8. PubMed ID: 28185914
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer.
Kaczmar J; Mehra R
Ther Adv Respir Dis; 2015 Oct; 9(5):236-41. PubMed ID: 26229087
[TBL] [Abstract][Full Text] [Related]
14. Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?
Franco R; Rocco G; Marino FZ; Pirozzi G; Normanno N; Morabito A; Sperlongano P; Stiuso P; Luce A; Botti G; Caraglia M
Expert Rev Anticancer Ther; 2013 Apr; 13(4):407-20. PubMed ID: 23560836
[TBL] [Abstract][Full Text] [Related]
15. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
Toyokawa G; Seto T
Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
[TBL] [Abstract][Full Text] [Related]
16. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
Eyre TA; Khan D; Hall GW; Collins GP
Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
[TBL] [Abstract][Full Text] [Related]
17. ALK inhibitors and advanced non-small cell lung cancer (review).
Rossi A; Maione P; Sacco PC; Sgambato A; Casaluce F; Ferrara ML; Palazzolo G; Ciardiello F; Gridelli C
Int J Oncol; 2014 Aug; 45(2):499-508. PubMed ID: 24889366
[TBL] [Abstract][Full Text] [Related]
18. Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS.
Klempner SJ; Ou SH
Chin Clin Oncol; 2015 Jun; 4(2):20. PubMed ID: 26112806
[TBL] [Abstract][Full Text] [Related]
19. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition.
Roskoski R
Pharmacol Res; 2013 Feb; 68(1):68-94. PubMed ID: 23201355
[TBL] [Abstract][Full Text] [Related]
20. Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.
Solomon B; Wilner KD; Shaw AT
Clin Pharmacol Ther; 2014 Jan; 95(1):15-23. PubMed ID: 24091716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
